Pharma Exclusives Pressreleases
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony
Friday, June 27, 2025Vetter a leading globally operating Contract Development and Manufacturing Organization CDMO celebrated the start of construction for its new clinical manufacturing site in Des Plaines with an official groundbreaking ceremony
Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Tuesday, June 24, 2025Novo Nordisk today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion for an update of the Ozempic
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
Monday, June 23, 2025Novo Nordisk today presented results from the phase b FRONTIER trial showing that a direct switch to investigational Mim denecimig prophylaxis from emicizumab treatment without a washout period
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Monday, June 23, 2025Roche announced today positive phase III data on NXT in people with haemophilia A supporting its progression into phase III clinical development NXT is a nextgeneration investigational bispecific antibody
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Saturday, June 21, 2025The US Food and Drug Administration FDA has approved Dupixent dupilumab for the treatment of adult patients with bullous pemphigoid BP BP primarily affects elderly patients and is characterized by intense itch painful blisters and lesions as well as...
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Saturday, June 21, 2025Rochepresented today results from the phase III SUNMO NCT study showing Lunsumio mosunetuzumab administered subcutaneously in combination with Polivy polatuzumab vedotin demonstrated
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Friday, June 20, 2025Ipsen announced today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has issued a positive opinion for Cabometyx cabozantinib for adult patients with unresectable
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Thursday, June 19, 2025Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announces positive topline clinical results from Part of a Phase b multiple ascending dose MAD trial
NUZ-001 Shows Promise in Zebrafish Model of Huntington’s Disease
Tuesday, June 17, 2025Neurizon Therapeutics Limited a clinicalstage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases is pleased to announce new preclinical data demonstrating
Bayer files for approval of gadoquatrane in the U.S.
Tuesday, June 17, 2025FDA submission seeks approval for investigational low dose gadoliniumbased contrast agent GBCA gadoquatrane for contrastenhanced magnetic resonance imaging MRI of the central nervous system CNS
